Catalent has announced the completion of its clinical supply facility expansion in China’s Waigaoqiao Free Trade Zone (FTZ).

Following the expansion of the facility in Shanghai, the site increased by nearly 30,000ft².

This allowed the installation of additional refrigerated (between 2°C and 8°C) and deep-frozen (between -70°C and -90°C) storage.

In addition, the project resulted in the expansion of secondary packaging capabilities at the clinical supply facility.

Catalent APAC Operations general manager Tracey Clare said: “China is the fastest growing clinical trials market in the Asia-Pacific region, and Catalent continues to invest and expand its facilities and services to offer reliable, flexible, and integrated support to customers.

“These additional capabilities increase the site’s ability to support clinical trials for advanced therapeutics, which often require specialised storage and handling capabilities.”

The facility in Waigaoqiao is one of two clinical supply facilities operated by Catalent in Shanghai.

The company is operating the first facility in Tangzhen, outside the FTZ.

These two facilities jointly provide optimised supply solutions to sponsors for clinical trials that are being undertaken in China, and through the extensive network of Catalent, the Asia-Pacific region and across the globe.

The solutions include comparator sourcing, clinical supply management, FastChain demand-led supply, storage, primary and secondary packaging, and worldwide distribution, as well as clinical returns and destruction.

In September this year, Catalent announced an expansion with a $2.2m investment in its clinical supply facility in Singapore.

The investment was aimed at increasing the site’s footprint by nearly 20% to 31,000ft², and allowed 35 new freezers to be installed for ultra-low temperature storage.